NCT05876312View on ClinicalTrials.gov

Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 7, 2023

Primary Completion Date

March 30, 2026

Study Completion Date

September 30, 2026

Conditions
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions
DRUG

ADX-038

siRNA duplex oligonucleotide

DRUG

Placebo

Saline

Trial Locations (4)

3000

NOT_YET_RECRUITING

Peter MacCallum Cancer Centre, Melbourne

3052

NOT_YET_RECRUITING

Royal Melbourne Hospital, Parkville

4006

RECRUITING

Nucleus Network Brisbane, Brisbane

SE1 1YR

RECRUITING

Richmond Pharmacology Ltd, London

Sponsors
All Listed Sponsors
collaborator

ADARx Australia Pty Ltd

UNKNOWN

collaborator

Novotech (Australia) Pty Limited

INDUSTRY

lead

ADARx Pharmaceuticals, Inc.

INDUSTRY